Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 42Nivolumab 13Carboplatin 11Cyclophosphamide 10olaparib 7Paclitaxel 7Ipilimumab 7fludarabine 6Gemcitabine 6durvalumab 5lenvatinib 4cemiplimab 4atezolizumab 4Specimen Handling 4Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fulvestrant 4Fluorouracil 4Cisplatin 4Bevacizumab 4veliparib 3spartalizumab 3sacituzumab govitecan 3liposomal doxorubicin 3avelumab 3aldesleukin 3Taxes 3Interleukin-2 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × vistusertib × Gynecologic × Clear all
NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡